Table 2.
Day 42 MRD levels among patients with Ph+ ALL treated in the pre- and post-TKI era
| ID number |
Tyrosine kinase inhibitor |
MRD level (%) by | |
|---|---|---|---|
| Flow cytometry | PCR amplification of Ig/TCR genes |
||
| 1 | None | 19 | 23 |
| 2 | None | 0.74 | |
| 3 | None | 4.76 | 3.6 |
| 4 | None | Not tested* | |
| 5 | None | 0.61 | 2.3 |
| 6 | None | 2.9 | |
| 7 | None | <0.01 | |
| 8 | None | 1.51 | |
| 9 | None | 0.05 | |
| 10 | None | 5 | |
| 11 | None | 0.21 | 0.23 |
| 12 | None | 0.29 | 0.023 |
| 13 | None | <0.01 | <0.01 |
| 14 | None | 4.52 | 5.20 |
| 15 | None | 12.57 | |
| 16 | None | 1.34 | |
| 17 | Imatinib | 0.06 | 0.09 |
| 18 | Imatinib | <0.01 | <0.01 |
| 19 | Imatinib | <0.01 | |
| 20 | Imatinib | <0.01 | <0.01 |
| 21 | Imatinib | <0.01 | <0.01 |
| 22 | Dasatinib | <0.01 | <0.01 |
| 23 | Dasatinib | <0.01 | |
| 24 | Dasatinib | <0.01 | |
| 25 | Dasatinib | <0.01 | |
| 26 | Dasatinib | 0.02 | |
| 27 | Dasatinib | <0.01 | |
*
17% blasts by morphology and t(9;22) (q34;q11.2) detectable by cytogenetic analysis